Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$43.52 USD
+0.67 (1.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $43.47 -0.05 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RNA 43.52 +0.67(1.55%)
Will RNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNA
Company News for Aug 13, 2024
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates
RNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Other News for RNA
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
These are the stocks with the largest changes in short interest in July - GS
Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Avidity Biosciences (RNA) and Veeva Systems (VEEV)
Promising Phase 1/2 Results for Avidity Biosciences Reinforce Buy Rating with New Price Objective